Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Affiliations

• ¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk.
• ² Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
• ³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
• ⁴ Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
• ⁵ Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK.
• ⁶ St Georges Vaccine Institute, St George's, University of London, London, UK.
• ⁷ Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy.
• ⁸ Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
• ⁹ Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain.
• ¹⁰ Charles University Prague, School of Medicine Hradec Kralove, Czech Republic.
• ¹¹ Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA.
• ¹² GSK Vaccines S.r.l., Siena, Italy.